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ABSTRACT 
Background Zidovudine therapy is of benefit in the treatment of symptomatic and 
asymptomatic human immunodeficiency virus (HIV) infection in persons with CD4+ 
cell counts of less than 500 per cubic millimeter. The efficacy, safety, and duration of 
benefit of zidovudine in those with 500 or more CD4+ cells per cubic millimeter are 
uncertain.  
Methods In a double-blind, placebo-controlled trial, 993 patients with asymptomatic 
HIV infection and CD4+ cell counts above 400 per cubic millimeter were randomly 
assigned to receive zidovudine (500 mg twice daily) or placebo for three years. The 
primary end point was progression of disease, as defined by the development of 
Centers for Disease Control and Prevention (CDC) group IV disease (including 
recurrent oral candidiasis, hairy leukoplakia, or progressive diarrhea) or two CD4+ 
cell counts below 350 per cubic millimeter. This outcome measure was changed from 
the original end point of the acquired immunodeficiency syndrome (AIDS) or 
advanced AIDS-related complex to reflect changes in recommendations for 
management. The study was terminated after the first interim analysis.  
Results Disease progression was significantly less frequent in the zidovudine group 
(relative risk, 0.56; 95 percent confidence interval, 0.43 to 0.75; P<0.001 by the log-
rank test). The probability of disease progression at two years was 0.19 with 
zidovudine, as compared with 0.34 with placebo (95 percent confidence interval for 
the difference, -0.21 to -0.08). Progression to CDC group IV disease was reduced by 
half in the zidovudine recipients (relative risk, 0.49; P = 0.049) and decline in CD4+ 
cell counts to below 350 per cubic millimeter was reduced by 40 percent (relative risk, 
0.60; P<0.001). The inclusion of early HIV disease events (oral candidiasis, oral hairy 
leukoplakia, and herpes zoster) as end points confirmed the effects of zidovudine on 
the progression of clinical disease (relative risk, 0.55; 95 percent confidence interval, 
0.37 to 0.84; P = 0.004). The median duration of treatment was 94 weeks. Severe 
hematologic or clinical side effects were rare.  
Conclusions Treatment with zidovudine benefits HIV-infected persons with CD4+ cell 
counts above 400 per cubic millimeter. Despite the use of doses larger than those 
now generally prescribed, zidovudine was well tolerated for up to three years by most 
of our patients.  
 
When our European-Australian Collaborative Group study was initiated, zidovudine had been 
shown to provide clinical benefit in patients with the acquired immunodeficiency syndrome 
(AIDS) or AIDS-related complex, including reductions in mortality and in the frequency of 
opportunistic infections1. While our study was under way, two other major placebo-controlled 
trials reported by the AIDS Clinical Trials Group demonstrated that treatment with zidovudine 
delayed disease progression in early symptomatic and asymptomatic patients with fewer than 
500 CD4+ cells per cubic millimeter2,3. Although a total daily dose of 1500 mg was used in 
the original study,1 the results of several trials3,4,5 have subsequently indicated that lower daily 
doses, between 500 and 600 mg, are equally effective for most patients.  
Since all the major placebo-controlled trials of zidovudine have been terminated early after 
interim analyses, long-term data on efficacy and safety have been available only from 
population studies6,7,8,9 or trials of dose ranges4,5. The Veterans Affairs study suggested that 
delayed zidovudine therapy resulted in more progression of disease than early intervention10. 
Differing opinions persist about the duration of benefit after intervention at different stages of 
human immunodeficiency virus (HIV) infection, and therefore about the optimal time to 
initiate treatment11,12,13. We report the results of a three-year study designed to determine the 
efficacy and safety of zidovudine in reducing disease progression in patients with early 
asymptomatic HIV infection and CD4+ cell counts above 400 per cubic millimeter. The trial 
was terminated in January 1992 after the first interim analysis.  
Methods 
Patient Population 
Patients at least 18 years old with asymptomatic HIV infection or persistent generalized 
lymphadenopathy were eligible for enrollment if they met the following criteria: a 
documented history of HIV-antibody seropositivity (i.e., at least two confirmed positive tests, 
one within three months of enrollment) and a CD4+ cell count above 400 cells per cubic 
millimeter within four weeks before entry. All patients gave written informed consent before 
participation in the study. Subjects were recruited from 56 centers in Australia, Austria, 
Belgium, Denmark, Finland, Germany, Iceland, Luxembourg, Norway, and Spain. Approval 
from the ethics committee at each center was obtained before the start of the study.  
Study Design 
The study was designed as a randomized, placebo-controlled parallel-group trial. At 
enrollment, the patients were randomized according to a permuted-blocks scheme, stratified 
according to center, in which the block size was six patients. When the study began in 1988, 
the primary clinical end point was the development of AIDS or severe AIDS-related complex. 
In 1989, after the preliminary reports of the two studies by the AIDS Clinical Trials Group, 
the International Coordinating Committee recognized that it had become unacceptable not to 
offer open-label treatment with zidovudine to persons whose CD4+ cell counts had fallen 
below 200 per cubic millimeter, even if they remained asymptomatic. Accordingly, patients 
were allowed optional withdrawal from the study if their CD4+ counts were less than or equal 
to 200 cells per cubic millimeter. Then, during 1990, the results of these studies were 
published,2,3 leading to an extension of the licensed indications for zidovudine and to further 
changes in medical practice. Although medical practice differed in some participating 
countries, a consensus was reached that persons with disease that met the criteria for group IV 
of the Centers for Disease Control and Prevention (CDC) system or whose CD4+ cell counts 
dropped below 350 per cubic millimeter should also be offered zidovudine therapy. Hence, 
the final primary end point became the development of CDC group IV disease or the 
determination of two CD4+ cell counts below 350 per cubic millimeter on separate occasions 
at least one month apart, whichever occurred first. All changes in the study design and end 
points were made and formalized by the International Coordinating Committee without 
awareness of the assigned treatments.  
Treatment Regimen, Evaluation of Patients, and Follow-up 
Patients were randomly assigned to receive two 250-mg capsules of zidovudine or matching 
placebo by mouth every 12 hours for up to three years. Side effects were managed according 
to guidelines prepared before the start of the study. Dose reduction to 250 mg every 12 hours 
or the permanent discontinuation of therapy was recommended when there was evidence of 
progressive bone marrow suppression or any other adverse reaction deemed sufficiently 
serious. The use of other drugs thought to have antiretroviral activity and the use of 
immunomodulatory agents were prohibited.  
After enrollment and base-line laboratory evaluation, patients were assessed every 4 weeks 
until week 24 and every 12 weeks thereafter. When possible, patients who were no longer 
receiving the study medication were followed every 12 weeks and assessed according to the 
protocol. Routine blood samples were monitored. Serum HIV p24 antigen levels and CD4+ 
cell counts were determined every 4 weeks until week 12 and every 12 weeks thereafter. Data 
on variables that might have led to unblinding (mean corpuscular volume and p24 antigen 
levels) were handled by staff members not involved with patient care or monitoring of the 
study.  
Assessment of End Points 
All definitions of study end points were formalized before the termination of the study. Data 
on each end point were reviewed by an End Points Committee. The investigators were asked 
to clarify end points when resolution of questionable diagnoses was required. End points were 
reviewed on an ongoing basis throughout the study, with all evaluations made by the End 
Points Committee carried out with the committee members unaware of the assigned treatments.  
Data were reviewed retrospectively in order to include end points of less advanced HIV 
disease and immunologic end points that had occurred before the changes to the end points 
were implemented. All information necessary for the newly defined end points had already 
been collected prospectively on the case-record forms. In the analyses, data on the end points 
were censored at the point of disease progression.  
For the purposes of this trial and in an attempt to standardize reporting across countries, 
modified but strict criteria for the conditions in CDC group IV-C2 were used. During the 
initial reviews of blinded data, the End Points Committee observed many reported secondary 
infections that were rejected as indicative of CDC group IV disease because of the strict 
criteria. The committee was, however, able to define an end point of clinical HIV disease that 
included early events of HIV disease as well as group IV events, whichever occurred first.  
There were four separate end points as defined by the End Points Committee. First, AIDS was 
defined on the basis of CDC criteria available at the start of the trial14. The protocol also 
specified, however, that peripheral neuropathy should be regarded as an AIDS-defining event. 
Severe AIDS-related complex was defined as unexplained weight loss of 7 kg or at least 10 
percent of body weight, unexplained oral candidiasis, or both, along with at least one of the 
following: progressive diarrhea for more than one month, fever (temperature >38 °C) 
persisting for more than one month without infectious cause, oral hairy leukoplakia, 
multidermatomal herpes zoster, and pulmonary tuberculosis. Second, modified criteria for 
conditions assigned to CDC group IV-C2 were used, as follows: oral candidiasis had to be 
documented on consecutive occasions at least three months apart, described at least once as 
moderate or severe and requiring topical therapy or at least once requiring systemic therapy; 
oral hairy leukoplakia had to be reported on consecutive occasions at least three months apart 
with a severity described as moderate or severe at least once or at least once requiring 
treatment with acyclovir; and herpes zoster had to be described as a widespread dissemination 
of rash involving nonadjacent dermatomes. Two patients with progressive diarrhea 
determined by the End Points Committee to have CDC group IV disease were analyzed as 
having CDC group IV-C2 disease. The analysis of progression to CDC group IV disease 
included patients with AIDS, severe AIDS-related complex, and CDC group IV-C2 disease. 
Third, the criteria for early clinical HIV disease were as follows: recurrent or persistent oral 
candidiasis or oral hairy leukoplakia when the occurrences were observed by the investigator, 
were documented by assessments at least 12 weeks apart, were otherwise unexplained, and 
did not fulfill our criteria for inclusion in CDC group IV-C2. In addition, localized herpes 
zoster infections were included in the analysis of early HIV disease. Analyses of progression 
to clinical HIV disease included patients with AIDS or severe AIDS-related complex, those in 
CDC group IV-C2, and those with early HIV disease. Fourth, the CD4+ end point was defined 
as the first time a patient's CD4+ cell count fell below 350 cells per cubic millimeter, provided 
that there was a subsequent and consecutive count also below 350 cells per cubic millimeter at 
least 28 days later.  
Data Management and Statistical Analysis 
Data from the participating centers were verified against selected source documents, including 
the patients' records of eligibility. Data were routinely dual-entered for verification and 
checked for anomalies and outliers.  
Variables related to the time to a critical event were analyzed by survival methods, including 
Kaplan-Meier estimates, log-rank tests, and determinations of relative risk. These variables 
were analyzed on an intention-to-treat basis. However, as specified in the study design, data 
were censored three months after the termination of blinded treatment with the study 
medication. The statistical significance of the primary objective was compared against a 
nominal significance level of 0.022, corresponding to an overall significance level of 0.05 
with allowance for two interim analyses. Other variables of interest were summarized with 
descriptive statistics, such as medians, tables, and 95 percent confidence intervals for 
treatment effects.  
The size of the study sample was recalculated in March 1991 after the amendment to the 
protocol that allowed the optional withdrawal of patients who had either a reduction in CD4+ 
cell count to less than 350 per cubic millimeter or progression to CDC group IV disease. The 
size of the revised sample was based on the objective of detecting a reduction from 20 percent 
to 10 percent in disease progression under the revised definition with use of the log-rank test 
with 90 percent power at the 0.05 significance level. An adjustment was made to allow for the 
interim analyses and for patient withdrawals. The calculations indicated that 836 patients 
would be required to show a treatment effect on disease progression as redefined above.  
 
 
 
Results 
Patient Population 
A total of 993 patients were enrolled in the trial between December 1988 and January 1992. 
The study was terminated in January 1992, when interim analysis showed a difference in 
overall disease progression that was significant at the P = 0.001 level. Of the 993 patients 
recruited, 9 were not included in the analyses of safety and efficacy because no follow-up 
information was available. A further eight patients were considered to have CDC group IV 
disease at entry and were therefore excluded from all analyses except those of safety. In 
addition, one patient was randomized twice by error.  
Of the 984 eligible patients, 489 were assigned to placebo and 495 to zidovudine. The 
demographic and clinical characteristics of the treatment groups were similar at entry (Table 
1). Median CD4+ cell counts at entry were similar in both groups (Table 1). The prevalence of 
positivity for HIV p24 antigen at entry was 11 percent in the placebo group and 9 percent in 
the zidovudine group. Other key clinical and laboratory measures were evenly matched 
between the two treatment groups. At the time of study termination, the median duration of 
treatment was 93 weeks for those assigned to placebo and 94 weeks for those assigned to 
zidovudine. Three hundred eight patients withdrew from blinded treatment during the study 
(Table 2).  
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Progress
ion of Disease 
Overall disease progression as defined in the protocol (progression to AIDS or severe AIDS-
related complex, CDC group IV-C2 disease, or two CD4+ cell counts below 350 per cubic 
millimeter) developed in 129 patients in the placebo group, as compared with 76 patients in 
the zidovudine group (relative risk, 0.56; 95 percent confidence interval, 0.43 to 0.75; 
P<0.001 by the log-rank test) (Figure 1). The number of patients whose disease progressed is 
shown according to base-line CD4+ cell count in Table 3, along with the overall risk ratio. 
The Kaplan-Meier probability of disease progression at two years was 0.34 in the placebo 
group and 0.19 in the zidovudine group (95 percent confidence interval for the difference, -
0.21 to -0.08) (Figure 1).  
  
 
  
Figure 1. Kaplan-Meier Estimates of Time to Study End Points in the Patients Assigned to 
Zidovudine and Placebo. 
The curves show the time to progression of disease as defined in the protocol, to CDC 
group IV disease, to a CD4+ cell count of less than 350 per cubic millimeter, and to clinical 
HIV disease.  
  
 
 
 
 
 
Table 3  
 
 
 
 
 
RISK RATIO 
BASE-LINE CD4+ CELLS (95% CONFIDENCE 
END POINT PER CUBIC MILLIMETER. OVERALL* INTERVAL) 
400-499 500- 749 > 750 
number (percent) 
Disease progression 
Zidovudine 24 (25) 37 (16) 6 (5) 76 (16) 0.56 (0-43-0.75) 
Placebo 58 (53) 52 (25) 12 (10) 129 (28) 
AIDS or severe 
AIDS-related 
complex 
Zidovudine 1 (I) 5 (2) 0 6 (1) 0 .59 (0.21-1.61) 
Placebo 1 (I) 6 (3) 3 (2) 10 (2) 
CDC group IV disease 
Zidovudine 2 (2) 8 (3) 1 (1) I I (2) 0.49 (0.24- 1. 01) 
Placebo 5 (4) 14 (7) 3 (2) 22 (5) 
Clinical HIV 
disease 
Zidovudine 6 (6) 21 (9) 4 (3) 35t (7) 0.55 (0.37- 0.84) 
Placebo 19 ( 17) 32 (15) 8 (6) 62 (13) 
CD4+ count 
<350/mm3 
Zidovudine 23 (24) 33 (14) 5 (4) 70 (15) 0.60 (0.44- 0.81) 
Placebo 55 (50) 42 (20) 9 (7) 11 3 (25) 
"Includes all end points regardless of base-line CD4+ cell count .nd therefore includes a 
group of subjects with base-line CD4+ cell counts of less than 400 per cubic millimeter. In the 
analyses of AIDS or severe AIDS-related complex, CDC group IV disease , and clinical HIV 
disease, the percentages shown were calculated on the bas is of the denominators used in the 
analysis of safety. Patients wilh CD4+ counts below 350 per cubic millimeter al entry and those 
with missing data on CD4+ counts at entry were excluded fram the analyses of disease 
progression and CD4+ count of less than 350 per cubic millimeter. 
tIncJudes ODe event in the zidovudine group in a patient for whorn base-liDe data on CD4+ 
cell counts were missing. 
  
Progression to AIDS or severe AIDS-related complex occurred in 10 patients assigned to 
placebo and 6 patients assigned to zidovudine (relative risk, 0.59; 95 percent confidence 
interval, 0.21 to 1.61; P = 0.29) (Table 3 and Table 4). Progression to CDC group IV disease 
occurred in 22 patients assigned to placebo, as compared with 11 assigned to zidovudine 
(relative risk, 0.49; 95 percent confidence interval, 0.24 to 1.01; P = 0.049) (Table 3 and Table 
4, Figure 1). The probability of progression to CDC group IV disease at two years was 0.06 in 
the placebo group, as compared with 0.03 in the zidovudine group (95 percent confidence 
interval for the difference, -0.06 to -0.01). Progression to a CD4+ cell count below 350 per 
cubic millimeter occurred in 113 recipients of placebo, as compared with 70 recipients of 
zidovudine (relative risk, 0.60; 95 percent confidence interval, 0.44 to 0.81; P<0.001) (Table 3 
and Figure 1). The probability of progression to a CD4+ cell count of less than 350 per cubic 
millimeter at two years was 0.32 in the placebo group, as compared with 0.17 in the 
zidovudine group (95 percent confidence interval for the difference, -0.21 to -0.07). 
Zidovudine significantly reduced the overall progression of disease as defined in the study, as 
well as delaying the onset of CDC group IV disease and the decline of CD4+ cell counts to 
below 350 per cubic millimeter.  
Table 4 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Sixty-two recipients of placebo and 35 recipients of zidovudine had clinical HIV disease 
(relative risk, 0.55; 95 percent confidence interval, 0.37 to 0.84; P = 0.004) (Table 3 and Table 
4, Figure 1). The probability of progression to clinical HIV disease at two years was 0.15 in 
the placebo group and 0.09 in the zidovudine group (95 percent confidence interval for the 
difference, -0.11 to 0.00).  
Compliance 
To assess compliance with study medication, the maximal mean corpuscular volumes were 
determined for patients receiving zidovudine and placebo. For 465 patients in the zidovudine 
group, the mean (±SD) maximal mean corpuscular volume was 110 ±10.5 microm3. For 468 
patients in the placebo group, the corresponding figure was 92.0 ±5.1 microm3. Only 5 percent 
of the placebo recipients had maximal mean corpuscular volumes above 100 microm3, and 10 
percent of the zidovudine recipients had maximal mean corpuscular volumes below 95 
microm3.  
Safety Data 
Severe hematologic or clinical side effects were rare in both groups. Only three patients in the 
zidovudine group (0.6 percent) had a hemoglobin count of less than 8 g per deciliter, whereas 
only 2 percent of patients in each treatment group had neutropenia involving <750 cells per 
cubic millimeter. Leukopenia (<1500 cells per cubic millimeter) developed in only one patient 
assigned to placebo. Thrombocytopenia (<50,000 cells per cubic millimeter) occurred in seven 
patients receiving placebo (1 percent) and in three patients receiving zidovudine (0.6 percent).  
Subjective symptoms were similar to those previously reported2,3. Symptoms reported more 
frequently in the zidovudine group included nausea (in 20 percent of the zidovudine group and 
8 percent of the placebo group), headache (in 12 percent and 6 percent, respectively), asthenia 
(8 percent and 2 percent), and anorexia (4 percent and 1 percent). The overall symptoms 
reported were of mild intensity. Otherwise, the frequency of events was very low or similar in 
the two treatment groups.  
The study treatments were well tolerated overall. Among the patients who remained in the 
study, 422 of 482 recipients of placebo (88 percent) and 385 of 492 recipients of zidovudine 
(78 percent) completed at least 90 percent of the study period without dose modification. 
Among the patients who did modify the dose, noncompliance was the most common reason 
for the initial modification, cited by 68 recipients of placebo (14 percent) and 87 recipients of 
zidovudine (18 percent). In only 15 of those receiving placebo (3 percent) and 35 of those 
receiving zidovudine (7 percent) was the first dose modification reported to be due to 
hematologic side effects. Subjective symptoms associated with nausea and headache (alone or 
in combination with other symptoms) were given as the reason for the first dose modification 
in 8 (2 percent) and 4 (1 percent), respectively, of the placebo recipients and 30 (6 percent) 
and 17 (3 percent) of the zidovudine recipients.  
 
 
 
 
Discussion 
In this large long-term, randomized, double-blind, placebo-controlled trial, zidovudine 
significantly reduced disease progression overall in patients with early asymptomatic HIV 
infection and CD4+ cell counts above 400 per cubic millimeter. Over a three-year period, the 
probability of progression to CDC group IV disease, CD4+ cell counts of less than 350 per 
cubic millimeter, or both was reduced by approximately half by treatment with zidovudine. 
These results are consistent with those of previous studies in asymptomatic HIV infection3 
and early symptomatic HIV disease2 in patients with fewer than 500 CD4+ cells per cubic 
millimeter. In addition, they provide the first evidence of similar benefit for persons with early 
asymptomatic HIV infection whose CD4+ cell counts are above 500 per cubic millimeter and 
indicate that such benefits are maintained for more than 2 1/2 years in those with more than 
400 CD4+ cells per cubic millimeter.  
Given the necessary modifications to the protocol, it was expected that the number of patients 
with progression to CDC group IV disease during the study would be limited. Nevertheless, 
the risk of such progression was reduced by approximately half by treatment with zidovudine. 
Among the remaining patients in whom symptoms and signs of HIV disease developed, the 
End Points Committee was able to use the end point of clinical HIV disease, which included 
events of early HIV disease as well as those of CDC group IV disease. Nonetheless, 59 
patients had events of clinical HIV disease reported by their physicians that did not meet the 
study criteria and were not included in the analysis of clinical HIV disease. Since these events 
were also approximately twice as common in the placebo group, their occurrence serves to 
strengthen our conclusions and to support the validity of events of clinical HIV disease as a 
marker of more serious progression of disease in this patient population.  
The reduction in the development of clinical HIV disease was not limited to patients with 
lower CD4+ cell counts at base line. The hazard ratio for progression to clinical HIV disease 
in patients with 500 to 749 CD4+ cells per cubic millimeter indicates a reduction in the risk of 
almost half. Although patients with 400 to 499 CD4+ cells per cubic millimeter may be at 
higher immediate risk of progression of clinical disease, these data arouse concern about 
current guidelines for intervention that are based only on CD4+ cell counts below 500 per 
cubic millimeter.  
Progression to CD4+ cell counts below 350 per cubic millimeter was also significantly 
reduced by zidovudine therapy. Overall, the risk of progression was 40 percent less in the 
zidovudine group than in the placebo group. As expected, patients with lower base-line CD4+ 
cell counts were more likely to reach this end point during the study, although similar benefits 
were observed in both strata of patients with less than 750 CD4+ cells per cubic millimeter 
(400 to 499 and 500 to 749). These data support the use of an end point based on CD4+ cell 
count as a surrogate marker of clinical disease progression.  
The zidovudine dosage of 500 mg twice daily was selected before the efficacy of doses of 500 
to 600 mg per day had been demonstrated4,5. It would seem reasonable to infer that lower total 
daily doses might have been equally effective, but it has not yet been established that they can 
be given in two divided doses. Despite the use of a higher daily dose of zidovudine in this 
study than is routinely used in current practice, the drug was well tolerated by the majority of 
patients. The frequency of hematologic toxicity was very low in both groups. The nature of 
subjective side effects was similar to that reported elsewhere3. Nevertheless, these findings are 
encouraging, because the average follow-up was almost twice as long as previously reported3.  
Concern has been expressed about the duration of benefit from zidovudine11,12,13. In our study 
clinical and immunologic effects of therapy were clearly evident at 2 1/2 years and may 
extend for at least 3 years. There are now data demonstrating the drug's efficacy at all stages 
of HIV disease apart from primary HIV infection. When all available data are considered, it is 
apparent that major benefit may be limited to 6 to 12 months in patients with advanced HIV 
disease,7 1 to 2 years in those with CD4+ cell counts from 200 to 400 per cubic millimeter,15 
and perhaps 2 to 3 years in those with earlier stages of HIV infection. This would be entirely 
consistent with the development of clinical failure in more advanced HIV disease in 
association with changes in virologic markers, including resistance to zidovudine16,17,18. All 
these factors argue for early intervention with zidovudine in order to obtain the most 
prolonged benefit and allow patients to maintain a good quality of life.  
Another issue is whether early intervention would be associated with longer survival than 
would treatment in the advanced stages of HIV disease. One study has suggested that early 
treatment offers no survival benefit, but both treatment groups had relatively advanced disease 
and the distinction between early and late therapy appeared to be very limited10. A preliminary 
report from the Concorde study has also indicated that immediate treatment with zidovudine 
provided no survival advantage as compared with deferred treatment19. Population studies, 
however, have suggested that in asymptomatic patients with fewer than 200 CD4+ cells per 
cubic millimeter zidovudine treatment provides a survival benefit of at least six months, but 
this may increase with intervention at higher CD4+ cell counts6. Although such benefits are 
obviously finite, it might be expected that survival could ultimately be improved with very 
early antiretroviral therapy. Hence, treatment strategies now under evaluation should be 
addressing ways of providing a substantially more sustained response before advanced disease 
develops. Nevertheless, the results presented here indicate that zidovudine monotherapy in 
early asymptomatic HIV-infected persons with more than 400 CD4+ cells per cubic 
millimeter is beneficial and well tolerated.  
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